Introduction: The standard of care for reversal of opioid-induced respiratory depression
INTRODUCTION
Over the last decade, opioid-related deaths have increased at an alarming rate resulting in a growing public health concern in the United States. There were more than four times as many opioid-related fatalities in 2010 as there were in 1999 [1] and opioid-related fatalities have remained at these levels through 2013 [2] [3] [4] .
This increase coincided with a nearly fourfold increase in the use of prescribed opioids for the treatment of pain [5] . Naloxone hydrochloride injection, used for four decades by trained emergency response personnel, is the first-line treatment to reverse life-threatening opioidinduced respiratory depression (OIRD) and overdose [6, 7] .
In the 1990s researchers began to investigate off-label administration of parenteral formulations of naloxone via the intranasal route of delivery and emergency medical technician units initiated pre-hospital intervention protocols using the intranasal route of naloxone administration in the early 2000s [8] . To further combat the growing opioid overdose crisis, members of the Harm Reduction Community began distributing naloxone nasal atomization kits (NXN) [9] . These organizations provide instructional sessions attended typically by the at-risk opioid users who are then expected to subsequently train their life partners, caregivers, or family members on the correct assembly and use of the kit.
The NXN consists of a glass cartridge containing a parenteral formulation of naloxone, a nasal atomizer (e.g., LMA Ò MAD Nasal TM [10] ; Teleflex Inc., Morrisville, NC, USA), personal protective equipment, and instructions-for-use. The instructions specify that the naloxone should be administered into each nostril of an individual suffering from OIRD. The intranasal route of naloxone administration is not approved by the United States Food and Drug Administration (FDA).
Therefore, use of this intranasal naloxone kit is considered an off-label use of naloxone. Additionally, the limited availability of naloxone combined with the level of training required to ensure correct assembly and use of the kit has been a barrier for wider community access to this potentially life-saving drug [11] .
A novel naloxone auto-injector (NAI), EVZIO Ò (naloxone hydrochloride injection; kaleo, Inc., Richmond, VA, USA), was specifically developed using state-of-the-art human factors engineering to address this unmet medical need. NAI was developed for immediate administration, with little to no training, by family members or caregivers of opioid overdose victims during an opioid emergency outside of a medically supervised setting. NAI provides voice instructions that assist in guiding the user through administration of a 0.4 mg dose of naloxone hydrochloride injection and contains a retractable needle system that conceals the needle before, during and after administration.
NAI was granted fast track designation and a priority review by the FDA. NAI is indicated for the emergency treatment of known or suspected opioid overdose as manifested by central nervous system or respiratory depression and is intended for immediate administration as emergency therapy in settings where opioids may be present [12] . 
METHODS

Participants
Healthy adult participants who were not severely visually impaired or hearing impaired were eligible to enroll. All participants were English language proficient. The participants had no prior experience with using, or being trained on, any naloxone delivery products and no relevant experience with similar nasal or injection delivery systems. 
Study Objectives
The primary objective of the study was to compare the usability of NAI and NXN in the administration of naloxone during a simulated opioid overdose emergency. The primary endpoint was successful administration of a simulated dose of naloxone into a simulated patient (mannequin) before and after receiving training without committing a Critical Task Error. Critical Task Error was defined as an error in essential task steps required to administer a clinically meaningful dose of naloxone successfully. The secondary endpoints were using the NAI or NXN in accordance with their instructions-for-use and the completion time of administration for NAI or NXN. Critical Task Errors, errors in adherence to instructions, and time to completion were measured. Subjective feedback was obtained for NXN and NAI after each use phase to facilitate evaluation of these errors and user preferences for each product.
Study Design
This was a single-site, randomized, open-label study. The study included three different phases. In phase 1, study participants were presented with brief information on the use scenario, but were not provided any training on the use of the two products. The use environment simulated a home setting including chairs, coffee table, and the mannequin (simulated patient) located on a couch randomly assigned to face-up or face- Review Board. Study participants were blinded to study funding which was provided by kaleo, Inc.
Assessments of Usability
The participants were assessed for their ability to complete a successful administration of naloxone into a mannequin using both NAI and NXN. There were two simulation sessions where the tasks could not be completed (i.e., the user gave up or the simulation was terminated due to time), the participant's time was imputed with a value of 15 min.
Evaluation of Usability and Administration During Phase 1 and Phase 3
Correct use of medical products, including drug/device combination products can be defined as compliance with critical tasks or adherence to instructions. Adherence to instructions is a measure of using the product as intended, including adherence to steps that may not strictly be required to deliver a clinically meaningful dose of naloxone.
Critical tasks for this study were those steps that are required to ensure successful naloxone administration resulting in a clinically meaningful dose of naloxone available for systemic absorption. For example, for NAI, the drug is indicated for subcutaneous or intramuscular use and the instructions-for-use states to inject into the outer thigh. However, an injection into commonly accepted subcutaneous or intramuscular locations of the abdomen, thigh, deltoid, or buttocks would be expected to deliver an effective dose. Therefore, if a participant injected NAI into the deltoid of the mannequin, it would be coded as a use error for adherence to the instructions-for-use, but not as a critical use error. Similarly, for NXN, the instructions-for-use indicates administering exactly half the dose (1 mL) into each nostril;
however, this may not be required to achieve a clinically meaningful effective dose. Therefore, the critical task for NXN was defined as administering any quantity of naloxone into both nostrils, assuming that some exposure to both nostrils would permit absorption of a sufficient quantity of naloxone from the nasal mucosa.
Statistical Analyses
Descriptive statistics were calculated to summarize continuous measures. Frequency count/percentages were used for summarizing categorical measures. For each product, the proportions of participants who would have successfully administered a clinically meaningful dose were reported as counts and percentages. Success was defined as not committing any use errors on each product's critical tasks as presented in Table 1 as well as the ability to use each product according to the product's instructions-for-use as presented in Table 2 .
The ability to administer NAI and NXN in accordance with each product's instructionsfor-use was also assessed and reported as counts and percentages.
McNemar's test was performed for comparison of critical task success as well as adherence to instructions-for-use success for NAI and NXN between phase 1 and phase 3.
Wilcoxon rank-sum test performed as sensitivity analysis for time to task completion for comparison between NAI and NXN within each phase (phase 1 and phase 3), and NAI or NXN between phase 1 and phase 3.
RESULTS
Participants
A total of 42 healthy participants between 18 and 65 years of age were enrolled in this study. The demographics and baseline characteristics of the participants are shown in Table 3 . The mean age was 41 ± 13.4 years for the participants. There were 45.2% male and 54.8% female participants.
All 42 participants completed the study.
Usability and Administration of NAI and NXN
During phase 1, 90.5% of participants completed a successful injection using NAI on the first attempt with no prior training or instruction leaflets versus 0.0% using NXN for the simulated opioid overdose scenario (P\0.0001). Phase 2 resulted in all participants successfully completing a one-on-one training session with a nurse, which included each participant demonstrating successful use of each naloxone product. Seven to eight days after the training session, participants returned for phase 3 and repeated the simulation. During phase 3, 100% of participants successfully administered a simulated naloxone dose using NAI versus only 57.1% using NXN (P\0.0001).
Task completion time for NAI was 0.9 ± 0.25 min for phase 1 (untrained) and 0.5 ± 0.15 min for phase 3 (post-training).
NXN task completion time for phase 1 was 6.0 ± 4.76 min and 2.0 ± 2.15 min for phase 3.
Participant Completion of Critical Tasks
Each product's critical tasks are detailed in The results are summarized in Table 4 .
The Critical Task Errors for NAI and NXN are shown in Table 5 . During phase 1 there were four Critical Task Errors for NAI. One error involved injection into an incorrect muscle, the calf, and three individuals failed to hold the auto-injector in place after the injection for at least one second. There were no Critical Task Errors for NAI during the phase 3 simulations.
For NXN, there were a total of 110 Critical Task Errors during Phase 1 simulations. None of the participants attempted to administer naloxone into both nostrils and 35 failed to administer naloxone into a single nostril. In addition, 32 participants leaked drug during assembly, 7 did not assemble the naloxone cartridge into the syringe correctly, 27 failed to attach the atomizer to the syringe, and 2 did not remove the yellow protective caps from the syringe.
For phase 3 simulations with NXN, there were 31 Critical Task Errors, which included 15 
Participant Adherence to
Instructions-for-Use
The instructions-for-use for each product are shown in Table 2 The results are summarized in Table 6 .
The use errors associated with failure to adhere to the instructions-for-use are shown in Table 7 . There were six errors in adherence to instructions for using NAI during phase 1; in addition to the NAI Critical Task errors, two individuals held NAI naloxone 0.4 mg auto-injector, NXN naloxone nasal atomization kit the NAI longer than one second, the minimum, but less than the 5-s countdown.
There were no errors in the adherence to The time differences for the study participants to administer a dose of naloxone to the simulated patient (Table 8) and that there is a place for a nasally administered naloxone product in the emergency treatment of OIRD [8, [15] [16] [17] [18] [19] [20] . This In addition, the safety and efficacy of the intranasal route of naloxone administration has not been subject to FDA review and approval, including in special populations such as pediatric patients suffering from unintentional opioid poisoning. Naloxone is effective in the treatment of opioid overdose only if it is: (1) available for administration, (2) administered correctly by the user, and (3) administered in a timely fashion as early intervention is often the determinant outcome when faced with a life-threatening OIRD event
Data presenting success of the nasal naloxone kits have been primarily based upon qualitative, observational surveys of needle exchange clinics and other harm reduction centers that distribute naloxone kits [22] .
These surveys collect data based on responses to questions including the number of overdose reversals reported over a specific period of time, but do not ask questions regarding the number of patients requiring alternative treatment due to incorrect usage of the naloxone nasal kit or the number of overdoses that occurred despite the naloxone nasal kit being dispensed, but not readily available during the overdose. Despite initial enthusiasm for the naloxone kit products and evidence of their life-saving potential, unanswered questions remain regarding their availability, usability and effectiveness in treatment of suspected opioid overdose.
One challenge associated with generic naloxone products, including vials and syringes as well as the NXN kit is the lack of unified instructions-for-use or patient counseling information [23] . In the case of this study, the NXN component product labeling [23] may have confused users, contributing to Critical Task Errors. For example, the carton in which the naloxone is provided for NXN describes use by ''intravenous, intramuscular, or subcutaneous'' parenteral routes and the pre-filled syringe looks like a delivery system intended for parenteral administration (Fig. 1 ) [23] . This is an inherent flaw associated with the NXN kits in which the user is provided written instructions and visual cues that are contrary to the intended nasal use of the product.
Therefore, without the benefit of training, many participants attempted to mimic parenteral administration, confusing the atomizer as a needle. Moreover, the naloxone carton has a small surface that provides limited instructions for assembly, but since the atomization device is included separately, the instructions have no guidance for its further assembly onto the pre-filled syringe to create the finished NXN [23] . (Fig. 2) [12] . The product includes a voice instruction system that assists in guiding users through the correct administration process. Therefore, although the supplemental instructions-for-use documents were not provided to the participants, the participants were able to rely on instructions built into the product. In addition, the administration of NXN required eight steps compared to five steps for NAI (Table 2 ). For NXN, some of the defined steps required multiple actions such as removing two caps from the syringe or the inherent need to remove the different components from different packages.
Therefore, participants had more opportunities to fail in adhering to instructions or completing critical tasks.
The results of this study should be viewed in light of the limitations of the study and its specific design to test a ''worst-case'' scenario. First, the assignment of Critical Task Errors for NXN required the determination of a ''clinically meaningful dose.'' Because nasally administered naloxone is not an FDA approved route of administration, the selection of the dose was based on published literature in which a full dose of 1 mL is administered into each nostril [8, [15] [16] [17] [18] . Several studies describe the need for additional doses of naloxone, therefore, the study team viewed the full dose of NXN as the minimally effective amount [24, 25] . Moreover, administration into both nostrils is listed as a required step in the instructions-for-use and in the published clinical studies. Therefore, administration into both nostrils was deemed a critical task; however, the study team permitted administration of a partial dose to both nostrils to meet the standard for a critical task, while administration of approximately 1 mL into each nostril was required for adherence to instructions. It is unknown if administration of some amount of naloxone into a single nostril is efficacious in some or all suspected overdose cases, and it is unknown how much of the full dose (2 mL) is required to be administered into the two nostrils to result in a clinically meaningful benefit. Second, because this study was designed to evaluate a ''worstcase'' scenario, both simulation phases of this study, before and after training, were conducted without the benefit of instructions-for-use leaflets for the participants. There were numerous errors associated with the assembly and administration of NXN which may have been mitigated if the users had the benefit of clear visual and written instructions, especially instructions that replaced those that were on the outer packaging of the naloxone glass syringe. However, the likelihood of users for NXN and NAI to both have access to instructional leaflets as well as refer to instructional leaflets during an opioid overdose emergency is low given the nature of an opioid overdose emergency.
Despite these study limitations, the data demonstrates that in a setting where a layperson is required to administer naloxone, they have a significantly higher success rate at administering a clinically meaningful dose using NAI versus NXN, and they complete the task utilizing NAI in less time than is required using NXN. The improved completion time from phase 1 to phase 3 for NAI and NXN underscores the effect training has on a user's ability to quickly administer each product for Finally, all study participants reported that they would have confidence in using NAI in an actual emergency whereas only one individual, post-training, indicated he would be confident in using NXN during a suspected opioid overdose emergency.
Participants attributed their confidence in using NAI to the limited number of steps required to complete an injection, the 
